Tanios Bekaii-Saab MD

Tanios Bekaii-Saab MD
Assoc ProfessorCollege of Medicinebekaii-saab.1@osu.edu
A 454 Starling Loving Hall 320 W 10th Avenue Columbus Ohio 43210
Phone:614-293-9863Fax: (614) 293-4372
  • Translational Therapeutics

Research Description

Dr. Bekaii-Saab's research interests include experimental therapeutics/translational research focused on molecularly-targeted and immune-mediated therapies in gastrointestinal (GI) cancers, and more specifically pancreas and biliary cancers. He is the principal investigator on numerous clinical trials, including studies supported through research grants from the National Cancer Institute (NCI) and the National Comprehensive Cancer Network (NCCN).

Current Publications

  • Knox JJ, Qin R, Strosberg JR, Tan B, Kaubisch A, El-Khoueiry AB, Bekaii-Saab TS, Rousey SR, Chen HX, Erlichman CA phase II trial of bevacizumab plus temsirolimus in patients with advanced hepatocellular carcinoma.Invest New Drugs in press 10/16/2014
  • Markowitz J, Brooks TR, Duggan MC, Paul BK, Pan X, Wei L, Abrams Z, Luedke E, Lesinski GB, Mundy-Bosse B, Bekaii-Saab T, Carson WEPatients with pancreatic adenocarcinoma exhibit elevated levels of myeloid-derived suppressor cells upon progression of disease.Cancer Immunol Immunother in press 10/11/2014
  • Nichols SD, Albert S, Shirley L, Schmidt C, Abdel-Misih S, El-Dika S, Groce JR, Wu C, Goldberg RM, Bekaii-Saab T, Bloomston MOutcomes in Patients with Obstructive Jaundice from Metastatic Colorectal Cancer and Implications for Management.J Gastrointest Surg in press 10/10/2014
  • Jaremka LM, Andridge RR, Fagundes CP, Alfano CM, Povoski SP, Lipari AM, Agnese DM, Arnold MW, Farrar WB, Yee LD, Carson WE, Bekaii-Saab T, Martin EW, Schmidt CR, Kiecolt-Glaser JKPain, depression, and fatigue: Loneliness as a longitudinal risk factor.Health Psychol 33 948-57 9/1/2014
  • Serrano PE, Herman JM, Griffith KA, Zalupski MM, Kim EJ, Bekaii-Saab TS, Ben-Josef E, Dawson LA, Ringash J, Wei ACQuality of Life in a Prospective, Multicenter Phase 2 Trial of Neoadjuvant Full-Dose Gemcitabine, Oxaliplatin, and Radiation in Patients With Resectable or Borderline Resectable Pancreatic Adenocarcinoma.Int J Radiat Oncol Biol Phys in press 8/4/2014
  • Tejani MA, Ter Veer A, Milne D, Ottesen R, Bekaii-Saab T, Benson AB 3rd, Schrag D, Shibata S, Skibber J, Weiser M, Wilkinson N, Cohen SJSystemic Therapy for Advanced Appendiceal Adenocarcinoma: An Analysis From the NCCN Oncology Outcomes Database for Colorectal Cancer.J Natl Compr Canc Netw 12 1123-30 8/1/2014
  • Pant S, Martin LK, Geyer S, Wei L, Van Loon K, Sommovilla N, Zalupski M, Iyer R, Fogelman D, Ko AH, Bekaii-Saab TTreatment-related Hypertension as a Pharmacodynamic Biomarker for the Efficacy of Bevacizumab in Advanced Pancreas Cancer: A Pooled Analysis of 4 Prospective Trials of Gemcitabine-based Therapy With Bevacizumab.Am J Clin Oncol in press 7/25/2014
  • Bekaii-Saab T, Wu CSeeing the forest through the trees: A systematic review of the safety and efficacy of combination chemotherapies used in the treatment of metastatic colorectal cancer.Crit Rev Oncol Hematol 91 9-34 7/1/2014
  • Grothey A, Flick ED, Cohn AL, Bekaii-Saab TS, Bendell JC, Kozloff M, Roach N, Mun Y, Fish S, Hurwitz HIBevacizumab exposure beyond first disease progression in patients with metastatic colorectal cancer: analyses of the ARIES observational cohort study.Pharmacoepidemiol Drug Saf 23 726-34 7/1/2014
  • Haraldsdottir S, Hampel H, Wei L, Wu C, Frankel W, Bekaii-Saab T, de la Chapelle A, Goldberg RMProstate cancer incidence in males with Lynch syndrome.Genet Med 16 553-7 7/1/2014
  • Pant S, Martin LK, Geyer S, Wei L, Van Loon K, Sommovilla N, Zalupski M, Iyer R, Fogelman D, Ko AH, Bekaii-Saab TBaseline serum albumin is a predictive biomarker for patients with advanced pancreatic cancer treated with bevacizumab: a pooled analysis of 7 prospective trials of gemcitabine-based therapy with or without bevacizumab.Cancer 120 1780-6 6/15/2014
  • Hurwitz HI, Bekaii-Saab TS, Bendell JC, Cohn AL, Kozloff M, Roach N, Mun Y, Fish S, Flick ED, Grothey A, ARIES Study InvestigatorsSafety and effectiveness of bevacizumab treatment for metastatic colorectal cancer: final results from the Avastin(®) Registry - Investigation of Effectiveness and Safety (ARIES) observational cohort study.Clin Oncol (R Coll Radiol) 26 323-32 6/1/2014
  • Lai IL, Chou CC, Lai PT, Fang CS, Shirley LA, Yan R, Mo X, Bloomston M, Kulp SK, Bekaii-Saab T, Chen CSTargeting the Warburg effect with a novel glucose transporter inhibitor to overcome gemcitabine resistance in pancreatic cancer cells.Carcinogenesis in press 5/30/2014
  • Van Loon K, Espinoza AM, Fogelman DR, Wolff RA, Javle MM, Iyer RV, Picozzi VJ, Martin LK, Bekaii-Saab T, Tempero MA, Foster NR, Kim GP, Ko AHShould combination chemotherapy serve as the backbone in clinical trials of advanced pancreatic cancer? A pooled analysis of phase II trials of gemcitabine-containing doublets plus bevacizumab.Pancreas 43 343-9 4/1/2014
  • Martin LK, Luu DC, Li X, Muscarella P, Ellison EC, Bloomston M, Bekaii-Saab TThe addition of radiation to chemotherapy does not improve outcome when compared to chemotherapy in the treatment of resected pancreas cancer: the results of a single-institution experience.Ann Surg Oncol 21 862-7 3/1/2014
  • Bekaii-Saab TMoving Forward With Expanding to an "All-RAS Mutational Analysis" in Metastatic Colorectal Cancer: Beyond KRAS Mutations.J Natl Compr Canc Netw 12 299-300 2/1/2014
  • Reyngold M, Niland J, ter Veer A, Milne D, Bekaii-Saab T, Cohen SJ, Lai L, Schrag D, Skibber JM, Small W Jr, Weiser M, Wilkinson N, Goodman KANeoadjuvant radiotherapy use in locally advanced rectal cancer at NCCN member institutions.J Natl Compr Canc Netw 12 235-43 2/1/2014
  • Bekaii-Saab T, Chen HX, Fuchs CS, Ng K, Rubinson DA, Hochster HS, Ryan DP, Wolpin BM, McCleary NJ, Abrams TA, Chan JA, Iqbal S, Lenz HJ, Lim D, Rose JMulti-drug inhibition of the HER pathway in metastatic colorectal cancer: results of a phase I study of pertuzumab plus cetuximab in cetuximab-refractory patients.Invest New Drugs 32 113-22 2/1/2014
  • Ahn DH, Bekaii-Saab TAmpullary cancer: an overview.Am Soc Clin Oncol Educ Book 112-5 1/1/2014
  • Seevaratnam R, Paszat L, Helyer L, Law C, Swallow C, Cardosa R, Mahar A, Lourenco LG, Dixon M, Bekaii-Saab T, Chau I, Church N, Coit D, Coburn N, Crane CH, Earle C, Mansfield P, Marcon N, Miner T, Noh SH, Porter G, Posner MC, Prachand V, Sano T, van de Velde C, Wong S, McLeod ROptimal management of gastric cancer: results from an international RAND/UCLA expert panel.Ann Surg 259 102-8 1/1/2014
  • Coburn NG, Brar SS, Mahar AL, Helyer LK, Swallow C, Law C, Paszat L, Seevaratnam R, Cardoso R, McLeod R, Dixon M, Yohanathan L, Lourenco LG, Bocicariu A, Bekaii-Saab T, Chau I, Church N, Coit D, Crane CH, Earle C, Mansfield P, Marcon N, Miner T, Noh SH, Porter G, Posner MC, Prachand V, Sano T, van de Velde C, Wong SProcesses of care in the multidisciplinary treatment of gastric cancer: results of a RAND/UCLA expert panel.JAMA Surg 149 18-25 1/1/2014
  • Garrett CR, Bekaii-Saab TS, Ryan T, Fisher GA, Clive S, Kavan P, Shacham-Shmueli E, Buchbinder A, Goldberg RMRandomized phase 2 study of pegylated SN-38 (EZN-2208) or irinotecan plus cetuximab in patients with advanced colorectal cancer.Cancer 119 4223-30 12/15/2013
  • Dixon M, Mahar A, Paszat L, McLeod R, Law C, Swallow C, Helyer L, Seeveratnam R, Cardoso R, Bekaii-Saab T, Chau I, Church N, Coit D, Crane CH, Earle C, Mansfield P, Marcon N, Miner T, Noh SH, Porter G, Posner MC, Prachand V, Sano T, Van de Velde CJ, Wong S, Coburn NWhat provider volumes and characteristics are appropriate for gastric cancer resection? Results of an international RAND/UCLA expert panel.Surgery 154 1100-9 11/1/2013
  • Haraldsdottir S, Bekaii-Saab TIntegrating anti-EGFR therapies in metastatic colorectal cancer.J Gastrointest Oncol 4 285-98 9/1/2013
  • Ciombor KK, Bekaii-Saab TEmerging treatments in recurrent and metastatic colorectal cancer.J Natl Compr Canc Netw 11 Suppl 4 S18-27 9/1/2013
  • Griffith KA, Francis IR, Greenson JK, Simeone DM, Lawrence TS, Laheru D, Wolfgang CL, Williams T, Bloomston M, Moore MJ, Wei A, Zalupski MM, Kim EJ, Ben-Josef E, Herman JM, Bekaii-Saab T, Dawson LAA multi-institutional phase 2 study of neoadjuvant gemcitabine and oxaliplatin with radiation therapy in patients with pancreatic cancer.Cancer 119 2692-700 8/1/2013
  • Brar S, Law C, McLeod R, Helyer L, Swallow C, Paszat L, Seevaratnam R, Cardoso R, Dixon M, Mahar A, Lourenco LG, Yohanathan L, Bocicariu A, Bekaii-Saab T, Chau I, Church N, Coit D, Crane CH, Earle C, Mansfield P, Marcon N, Miner T, Noh SH, Porter G, Posner MC, Prachand V, Sano T, van de Velde C, Wong S, Coburn N, International multidisciplinary expert panelDefining surgical quality in gastric cancer: a RAND/UCLA appropriateness study.J Am Coll Surg 217 347-57.e1 8/1/2013
  • Foy KC, Wygle RM, Miller MJ, Overholser JP, Bekaii-Saab T, Kaumaya PTPeptide vaccines and peptidomimetics of EGFR (HER-1) ligand binding domain inhibit cancer cell growth in vitro and in vivo.J Immunol 191 217-27 7/1/2013
  • Wu C, Fernandez SA, Criswell T, Chidiac TA, Guttridge D, Villalona-Calero M, Bekaii-Saab TSDisrupting cytokine signaling in pancreatic cancer: a phase I/II study of etanercept in combination with gemcitabine in patients with advanced disease.Pancreas 42 813-8 7/1/2013
  • Patnaik A, Papadopoulos KP, Tolcher AW, Beeram M, Urien S, Schaaf LJ, Tahiri S, Bekaii-Saab T, Lokiec FM, Rezaï K, Buchbinder APhase I dose-escalation study of EZN-2208 (PEG-SN38), a novel conjugate of poly(ethylene) glycol and SN38, administered weekly in patients with advanced cancer.Cancer Chemother Pharmacol 71 1499-506 6/1/2013
  • Mortazavi A, Ling Y, Martin LK, Wei L, Phelps MA, Liu Z, Harper EJ, Ivy SP, Wu X, Zhou BS, Liu X, Deam D, Monk JP, Hicks WJ, Yen Y, Otterson GA, Grever MR, Bekaii-Saab TA phase I study of prolonged infusion of triapine in combination with fixed dose rate gemcitabine in patients with advanced solid tumors.Invest New Drugs 31 685-95 6/1/2013
  • Bloomston M, Lesinski GB, Mace TA, Ameen Z, Collins A, Wojcik S, Mair M, Young GS, Fuchs JR, Eubank TD, Frankel WL, Bekaii-Saab TPancreatic cancer-associated stellate cells promote differentiation of myeloid-derived suppressor cells in a STAT3-dependent manner.Cancer Res 73 3007-18 5/15/2013
  • Freedman-Cass DA, National Comprehensive Cancer Network, Benson AB 3rd, Bekaii-Saab T, Chan E, Chen YJ, Choti MA, Cooper HS, Engstrom PF, Enzinger PC, Fakih MG, Fenton MJ, Fuchs CS, Grem JL, Hunt S, Kamel A, Leong LA, Lin E, May KS, Mulcahy MF, Murphy K, Rohren E, Ryan DP, Saltz L, Sharma S, Shibata D, Skibber JM, Small W Jr, Sofocleous CT, Venook AP, Willett CG, Gregory KMLocalized colon cancer, version 3.2013: featured updates to the NCCN Guidelines.J Natl Compr Canc Netw 11 519-28 5/1/2013
  • Martin LK, Bekaii-Saab TOptimizing neoadjuvant therapy for rectal cancer with oxaliplatin.J Natl Compr Canc Netw 11 298-307; quiz 307 3/1/2013
  • Willett CG, Gregory KM, Freedman-Cass DA, Benson AB 3rd, Bekaii-Saab T, Chan E, Chen YJ, Choti MA, Cooper HS, Engstrom PF, Enzinger PC, Fakih MG, Fenton MJ, Fuchs CS, Grem JL, Hunt S, Kamel A, Leong LA, Lin E, May KS, Mulcahy MF, Murphy K, Rohren E, Ryan DP, Saltz L, Sharma S, Shibata D, Skibber JM, Small W Jr, Sofocleous CT, Venook APMetastatic colon cancer, version 3.2013: featured updates to the NCCN Guidelines.J Natl Compr Canc Netw 11 141-52; quiz 152 2/1/2013
  • Crane CH, Earle C, Mansfield P, Marcon N, Miner T, Noh SH, Porter G, Posner MC, Prachand V, Sano T, Van de Velde CJ, Wong S, Coburn N, Dixon M, Seevaratnam R, Wirtzfeld D, McLeod R, Helyer L, Law C, Swallow C, Paszat L, Bocicariu A, Cardoso R, Mahar A, Bekaii-Saab T, Chau I, Church N, Coit DA RAND/UCLA appropriateness study of the management of familial gastric cancer.Ann Surg Oncol 20 533-41 2/1/2013
  • Bauer TM, El-Rayes BF, Li X, Hammad N, Philip PA, Shields AF, Zalupski MM, Bekaii-Saab TCarbohydrate antigen 19-9 is a prognostic and predictive biomarker in patients with advanced pancreatic cancer who receive gemcitabine-containing chemotherapy: a pooled analysis of 6 prospective trials.Cancer 119 285-92 1/15/2013
  • Bekaii-Saab T, Goldberg RMFOLFIRINOX in locally advanced pancreas adenocarcinoma: back to the future?Oncologist 18 487-9 1/1/2013
  • Martin LK, Bekaii-Saab T, Serna D, Monk P, Clinton SK, Grever MR, Kraut EHA phase I dose escalation and pharmacodynamic study of SU5416 (semaxanib) combined with weekly cisplatin and irinotecan in patients with advanced solid tumors.Onkologie 36 657-60 1/1/2013
  • Bertino EM, Bekaii-Saab T, Fernandez S, Diasio RB, Karim NA, Otterson GA, Villalona-Calero MAA phase II study of modulated-capecitabine and docetaxel in chemonaive patients with advanced non-small cell lung cancer (NSCLC).Lung Cancer 79 27-32 1/1/2013
  • Rose JS, Serna DS, Martin LK, Li X, Weatherby LM, Abdel-Misih S, Zhao W, Bekaii-Saab TInfluence of KRAS mutation status in metachronous and synchronous metastatic colorectal adenocarcinoma.Cancer 118 6243-52 12/15/2012
  • Martin MG, May KS, Mulcahy MF, Murphy K, Rohren E, Ryan DP, Saltz L, Sharma S, Shibata D, Skibber JM, Small W Jr, Sofocleous CT, Venook AP, Willett CG, Freedman-Cass DA, Gregory KM, Benson AB 3rd, Bekaii-Saab T, Chan E, Chen YJ, Choti MA, Cooper HS, Engstrom PF, Enzinger PC, Fakih MG, Fuchs CS, Grem JL, Hunt S, Leong LA, Lin ERectal cancer.J Natl Compr Canc Netw 10 1528-64 12/1/2012
  • Trolli E, Bekaii-Saab T, Martin LK, Wei LElevated baseline CA19-9 levels correlate with adverse prognosis in patients with early- or advanced-stage pancreas cancer.Med Oncol 29 3101-7 12/1/2012
  • Goldsmith SJ, Manzone T, Holt M, O'Neil BH, Hall N, Montero AJ, Kauh J, Gold DV, Horne H, Wegener WA, Goldenberg DM, Ocean AJ, Pennington KL, Guarino MJ, Sheikh A, Bekaii-Saab T, Serafini AN, Lee D, Sung MW, Gulec SAFractionated radioimmunotherapy with (90) Y-clivatuzumab tetraxetan and low-dose gemcitabine is active in advanced pancreatic cancer: A phase 1 trial.Cancer 118 5497-506 11/15/2012
  • Grecula J, Jia G, Wei L, Yang X, Otterson GA, Wu X, Harper E, Kefauver C, Zhou BS, Yen Y, Bloomston M, Knopp M, Ivy SP, Grever M, Bekaii-Saab T, Martin LKA dose escalation and pharmacodynamic study of triapine and radiation in patients with locally advanced pancreas cancer.Int J Radiat Oncol Biol Phys 84 e475-81 11/15/2012
  • Martin LK, Otterson GA, Bekaii-Saab TPhotodynamic therapy (PDT) may provide effective palliation in the treatment of primary tracheal carcinoma: a small case series.Photomed Laser Surg 30 668-71 11/1/2012
  • Kleiber B, Ellison EC, Bloomston M, Zalupski M, Bekaii-Saab TS, Martin LK, Li XVEGF remains an interesting target in advanced pancreas cancer (APCA): results of a multi-institutional phase II study of bevacizumab, gemcitabine, and infusional 5-fluorouracil in patients with APCA.Ann Oncol 23 2812-20 11/1/2012

The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) 300 W. 10th Ave. Columbus, OH 43210 Phone: 1-800-293-5066 | Email: jamesline@osumc.edu